Open-Label Extensions The Key To Gantenerumab Success, Stresses Roche

 
• By Jo Shorthouse
  
Generate a summary of this article
Listen to this article
Beta

Roche’s neuroscience strategy of following the science, taking on lessons from open label extensions from Phase III studies, is vital to the success of gantenerumab, the company said in an interview with Scrip.

Brain
• Source: Shutterstock

Roche remains hopeful that its anti-Alzheimer's antibody gantenerumab can prevail where so many other amyloid-beta-targeting antibodies have failed. Aside from the failure of its own crenezumab, the most recent clinical disappointment was that of Biogen Inc./Eisai Co. Ltd.’s aducanumab, in March. (Also see "Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis" - Scrip, 22 March, 2019.)

“It is too early for us to draw concrete, scientific learnings from Biogen’s announcement,” Rachelle Doody, global head of neurodegeneration...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D